GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (WBO:AMGN) » Definitions » Other Gross PPE

Amgen (WBO:AMGN) Other Gross PPE : €4,771 Mil (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Amgen Other Gross PPE?

Amgen's Other Gross PPE for the quarter that ended in Dec. 2024 was €4,771 Mil.

Amgen's quarterly Other Gross PPE increased from Jun. 2024 (€5,664 Mil) to Sep. 2024 (€14,827 Mil) but then declined from Sep. 2024 (€14,827 Mil) to Dec. 2024 (€4,771 Mil).

Amgen's annual Other Gross PPE declined from Dec. 2022 (€4,422 Mil) to Dec. 2023 (€4,414 Mil) but then increased from Dec. 2023 (€4,414 Mil) to Dec. 2024 (€4,771 Mil).


Amgen Other Gross PPE Historical Data

The historical data trend for Amgen's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Other Gross PPE Chart

Amgen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,907.79 3,944.45 4,421.70 4,413.52 4,771.18

Amgen Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,413.52 5,521.84 5,664.11 14,826.86 4,771.18

Amgen Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Amgen Business Description

Address
One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.